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Abstract
Background: Sexually-transmitted pathogens often have severe reproductive health implications if treatment is
delayed or absent, especially in females. The complex processes of disease progression, namely replication and
ascension of the infection through the genital tract, span both extracellular and intracellular physiological scales, and
in females can vary over the distinct phases of the menstrual cycle. The complexity of these processes, coupled with
the common impossibility of obtaining comprehensive and sequential clinical data from individual human patients,
makes mathematical and computational modelling valuable tools in developing our understanding of the infection,
with a view to identifying new interventions. While many within-host models of sexually-transmitted infections (STIs)
are available in existing literature, these models are difficult to deploy in clinical/experimental settings since
simulations often require complex computational approaches.
Results: We present STI-GMaS (Sexually-Transmitted Infections – Graphical Modelling and Simulation), an
environment for simulation of STI models, with a view to stimulating the uptake of these models within the laboratory
or clinic. The software currently focuses upon the representative case-study of Chlamydia trachomatis, the most
common sexually-transmitted bacterial pathogen of humans. Here, we demonstrate the use of a hybrid PDE–cellular
automata model for simulation of a hypothetical Chlamydia vaccination, demonstrating the effect of a
vaccine-induced antibody in preventing the infection from ascending to above the cervix. This example illustrates the
ease with which existing models can be adapted to describe new studies, and its careful parameterisation within
STI-GMaS facilitates future tuning to experimental data as they arise.
Conclusions: STI-GMaS represents the first software designed explicitly for in-silico simulation of STI models by non-
theoreticians, thus presenting a novel route to bridging the gap between computational and clinical/experimental
disciplines. With the propensity for model reuse and extension, there is much scope within STI-GMaS to allow clinical
and experimental studies to inform model inputs and drive future model development. Many of the modelling
paradigms and software design principles deployed to date transfer readily to other STIs, both bacterial and viral;
forthcoming releases of STI-GMaS will extend the software to incorporate a more diverse range of infections.
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Background
In this article we describe the recent development of a
novel software environment for modelling of sexually-
transmitted infections (STIs). Since STI progression can-
not be monitored within humans directly without being
highly invasive and expensive, mathematical modelling is
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a valuable strategy in elucidating infection dynamics and
evaluating the potential impact of new interventions [1].
Within-host modelling of STIs still being a relatively new
field, determining new treatments currently relies pri-
marily on animal trials. While some authors have sought
to integrate mathematical models with data from animal
experiments [2-5], there has to date been relatively lit-
tle uptake of mathematical models by non-theoreticians,
attributable (at least in part) to the fact that dynamic sim-
ulation of mathematical models relies upon the researcher
having sufficient knowledge of mathematical techniques
© 2014 Nelson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
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and computational strategies to generate simulations rele-
vant to their specific studies. To enhance the relevance of
model outputs, and strengthen the uptake of such models,
it is invaluable to enable the investigator to run sim-
ulations of a range of models with easily customisable
parameter sets and user-friendly visualisation of results.
We focus here upon the representative case study of
C. trachomatis infection—the most common sexually-
transmitted bacterial pathogen of humans, with over 105
million new adult cases occurring worldwide each year
[6]. Due to its lengthy (6–14 day) incubation period and
its high rate of asymptomatic infection, a large reser-
voir of C. trachomatis infection can accumulate in the
lower genital tract of both men and women, without early
detection. This reservoir presents a risk of an infection
ascending to the upper genital tract with resultant adverse
effects on reproductive health, including serious compli-
cations such as pelvic inflammatory disease (PID), tubal
factor infertility and ectopic pregnancies. AlthoughC. tra-
chomatis affects men, women and infants, women bear
the brunt of the chlamydial burden due to a higher risk of
adverse reproductive consequences. We focus here upon
C. trachomatis infection in females.
C. trachomatis is an obligate, intracellular bacterium; i.e.
its replication relies upon internalisation by a host cell of
the genital epithelium (as shown in Figure 1). The bac-
terium exists in two forms: the infectious form, termed
the elementary body (EB); and the intracellular replica-
tive form, termed the reticulate body (RB). The EB is
thought to be metabolically inert until it attaches to, and
is endocytosed by, a susceptible host epithelial cell. After
the EB attaches, it is rapidly ingested by an enhanced
phagocytic process similar to ordinary bacterial phago-
cytosis [7]. Within two hours of internalisation, the EB
differentiates into the metabolically active RB form. The
RB then multiplies 200–500-fold by binary fission [8],
before converting back into the infectious EB form. The
host cell eventually lyses, releasing the new EBs back
into the genital tract. The infection cycle then begins
anew.
A common starting point for many recent within-host
models of C. trachomatis is the model of [9], which
uses ordinary differential equations (ODEs) to describe
the temporal evolution of the chlamydial infection at the
tissue-scale. The model incorporates infection of epithe-
lial cells by EBs at a rate proportional to the concentration
of the infection; birth, natural death and lysis of epithelial
cells at prescribed rates; removal bymacrophages of extra-
cellular EBs; and removal of infected cells by elements
of the cell-mediated immune system. This model pro-
vides a robust foundation for modelling of C. trachomatis,
and has since been extended by many authors, includ-
ing [10] who incorporated a more thorough multi-stage
description of the intracellular EB replication process.
Recent studies by Mallet and co-workers [2,11-13]
have placed greater focus upon understanding the pro-
cesses through whichC. trachomatis infection ascends the
cervix. To incorporate the spatial dependence of extracel-
lular quantities, the ODE model of [9] is replaced with
a partial differential equation (PDE) analogue; extracellu-
lar particles are generally considered to move diffusively,
and the models are able to incorporate e.g. chemotactic
Figure 1 The C. trachomatis replication cycle. Initially a healthy epithelial cell is in the neighbourhood of extracellular chlamydiae. The cell
becomes infected by a single EB, which adheres to the surface of the cell (illustrated at 0 hours). The EB is quickly engulfed by the cell and converts
to the RB form within an inclusion (illustrated at 1–12 hours). RBs multiply approximately 500-fold by binary fission, and eventually convert back to
the infectious EB form. The cell ultimately lyses (48–72 hours), releasing these infectious EBs.
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terms to capture migration of immune cells in response to
diffusible chemical cues.
While PDE models succeed in qualitatively capturing
the ascension of the infection, they lack a robust descrip-
tion of cell-scale phenomena. In the model of [2], the
above PDE description of extracellular chlamydiae is com-
bined with a cell-based description of the epithelium, in
which each cell is modelled via a cellular automatonwhose
behaviour is governed by prescribed probabilistic rules.
We further describe and extend this hybrid model in the
forthcoming sections.
In the remainder of this article, we describe the develop-
ment of a new software environment for easy simulation
of a range of STI models, focusing on C. trachomatis
in particular. We then illustrate the use of the software
through a simple extension of the model of [2] to describe
immunisation of adolescent females. We then describe
scope for extensions of the software beyond the currently
available models, and to describe other STIs.
Implementation
To promote the use of mathematical and compua-
tional models by clinical and experimental researchers,
the authors have developed new software for easy STI
model simulation. This software environment, named
STI-GMaS (Sexually-Transmitted Infections – Graphical
Modelling and Simulation) has been designed with acces-
sibility and extensibility at its core, and makes progress
toward thorough curation and annotation of models to
clarify nomenclature, and maximise coherence between
different models and ultimately across multiple infections.
STI-GMaS is built upon a framework of existing tools
from within the Virtual Physiological Human (VPH)
Toolkit—an online repository of tools for interdisciplinary
modelling of the human physiome [14]. Integration with
the Toolkit provides direct access to a number of stan-
dards for model development, annotation and validation,
which (in the long-term) will allow STI-GMaS to be
integrated with a range of other software for simulation
of the wider physiome. Model simulations within STI-
GMaS are implemented through new and existing finite-
element tools provided by the open-source CHASTE
(Cancer, Heart and Soft Tissue Environment) project
[15-17], whose use provides on-going development in
terms of diversity of tools, computational efficiency
and cross-platform support. Furthermore, CHASTE’s
delevopment deploys a test-oriented approach that
ensures that algorithms are rigorously and regularly
validated [16]; STI-GMaS benefits directly from this
testing, and comparison with published results is
performed for any newly added model, to ensure that
simulation results are numerically accurate. For details
of the implementation and testing of CHASTE itself, the
reader is directed to [15-17].
STI-GMaS integrates the outputs of these CHASTE
simulations with visualisation tools to illustrate the bio-
logical phenomena that themodels predict. These compo-
nents are integrated via a graphical user interface (written
in Java), which is also responsible for providing clear
model annotation and parameterisation to enable models
to be easily redeployed by the non-theoretical user. STI-
GMaS is available on all 64-bit CHASTE-compatible oper-
ating systems, including linux, Mac OS X andWindows.
Figure 2 illustrates the workflow via which the various
components of STI-GMaS are integrated. On loading
STI-GMaS, the user is presented with a list of cur-
rently available models, categorised as either temporal
or spatio-temporal, and complemented with pop-up win-
dows to inform non-theoretical users as to which class
of models is most appropriate for their study. On select-
ing a model, the user arrives at a model-specific control
panel (Figure 3) through which they can select from a
number of default parameter sets (representing biolog-
ically important behaviours) or select new parameters
to examine potentially new phenomena, allowing for a
more thorough investigation of the model than may have
been afforded by its original publication. All user-defined
parameter sets can be saved and re-loaded for future
simulations.
The implementation of STI-GMaS has considered two
broad classes of end user: the clinician/experimentalist,
who will be able to run new simulations of existing mod-
els easily; and the theoretician, for whom the source code
is accessible for encoding of new models. To facilitate
the latter, templates have been created within STI-GMaS
to govern model parameteristion and enforce a mini-
mum level of model annotation. New models will be
required to meet these standards prior to being included
in future releases; STI-GMaS developers will work along-
side authors of new models to incorporate these as they
arise.
STI-GMaS is distributed as an open-source ‘bolt-on’
of CHASTE, is licensed under CHASTE’s 3-clause BSD
license, and can be downloaded via the STI-GMaS web-
site, or directly from the CHASTE homepage [18].
Results
Here, we demonstrate the use of STI-GMaS as an inves-
tigative tool for future interventions and treatment. We
consider a scenario in which adolescent females are to be
immunised with a Chlamydia vaccine prior to their sexual
debut, to circumvent the development of inflammation in
the Fallopian tubes: a common precursor to PID. The aims
of the vaccination could be achieved by halting the ascen-
sion of the C. trachomatis organism through the genital
tract, and by reducing the level of infection within the Fal-
lopian tubes to a level below that required to trigger an
inflammatory response.
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Figure 2 The STI-GMaS workflow. A user-friendly graphical user interface (written in Java) enables easy model selection and parameterisation,
and allows simulation of underlying models to be initiated using CHASTE. Results are passed to one of two visualisation tools, selected dependent
upon whether the model contains spatial information.
The modelling assumptions in the design of the vacci-
nation intervention are: (i) it takes at least 24 hours for
white blood cells to enter the tissue at the site of infec-
tion, (ii) the vaccine elicits a strong cell-mediated immune
response that becomes effective more quickly as a result
of the expansion of the antigen-specific T cell population,
and (iii) the vaccine enhances humoral immunity such
that an antibody response is already present in the cer-
vical secretions. The antibodies can combat the infection
in two ways: either by neutralising extracellular chlamy-
diae, preventing attachment to host cells; or by stimulating
phagocytosis of extracellular EBs, removing them from
the system.
We model the intervention through an extension of the
hybrid PDE–CA model of [2] (shown schematically in
Figure 4). In the following, we deploy nomenclature con-
sistent with [2]. In this model, extracellular EBs move
diffusively with concentration C(x, t), and healthy cells
become infected with probability proportional to the
number of extracellular EBs in their vicinity (as discussed
below). On infection, a cell is allocated a length of time
until lysis, drawn from an appropriate normal distribu-
tion, since infection prevents natural death by apoptosis.
On lysis, B new EBs are released, which appear as a
source term in the extracellular PDE. After lysis, the void
which remains in the cell monolayer is considered to
be immediately filled by a new healthy cell. The model
accounts for both innate and cell-mediated immune
responses: as the density of infected cells increases, so
does the strength of an emitted chemical infection signal
(I), which is used to calculate the likelihood with which
immune responses clear extracellular EBs or remove the
infected cell. The signal strength at a given cell location
increases while that cell remains infected; this infection
signal is also transmitted to neighbouring cells across
cell boundaries. If there are no infected cells in a given
neighbourhood, the local infection signal is subject to
exponential decay at a prescribed rate. The model incor-
porates delays between cell infection, activation of the
response and recruitment of immune cells to the infected
cell location. Each of the above infection and clearance
events occurs probabilistically with likelihood given by
Pr (event) = p (X; pmin, pmax,X1/2)
≡ pminpmaxe
kX
pmax + pmin
(
ekX − 1) , (1)
with
k = ln
( 0.5 (pmax − pmin)
pmaxpmin − 0.5pmin
)1/X1/2
. (2)
In (1–2), X represents either the local extracellular EB
concentration (C) or infection signal level (I), and X1/2 is
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Figure 3 A typical STI-GMaSmodel window. Each incorporated model is accessed through a control panel, which provides a citation and brief
description of the model, and allows for setting of each of the model’s parameters prior to running of a new simulation. Parameter nomenclature is
consistent with the model’s original publication; hovering over any parameter will display the meaning of that parameter as hover help.
the value of X for which Pr (event) = 0.5. Each infection
or clearance event is therefore described by three param-
eters: pmin, pmax and X1/2. We direct the reader to [2] for
further information regardingmodel parameters and their
values.
We now introduce a new variable A to represent the
vaccine-induced antibody level, and allow the model’s
original parameters to vary with A in the manner
described by (1). We assume that in the presence of
high levels of antibody, the maximum probability of cell
infection is reduced, and the minimum probability of EB
clearance is increased. In the nomenclature of the original
model, we let
pcellmax ∼ 1 − p
(
A; pAmin, pAmax,A1/2
)
, (3)
pEBmin ∼ p
(
A; pAmin, pAmax,A1/2
)
. (4)
The extent to which these quantities are adjusted is suit-
able for later fitting to experimental data through tuning
of the new parameters pAmin, pAmax and A1/2. We examine
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Figure 4 Schema of the model of Mallet (2009). Illustrated are the infection and clearance events incorporated in the model of [2], showing
parameterisation in the nomenclature of the model’s original publication. Cell infection occurs as a function of local extracellular particle number
(C), while clearance events are governed by a local infection signal (I), computed as a historic measure of the number of neighbouring cells to have
been infected. Each event occurs with likelihood given by (1), for parameters and inputs shown in red; associated delays are given in green. For a full
list of parameter values, see [2].
the progression of the infection under three antibody
levels: no antibodies (A = 0, A1/2 = 100; correspond-
ing to no vaccination), moderate antibody levels (A = 50,
A1/2 = 100), and high antibody levels (A = 100, A1/2 =
100). Typical values of other parameters are illustrated in
Figure 3 (in which nomenclature is as given in the original
paper), and parameter sets are provided in full within the
STI-GMaS software as model ‘Nelson2014’.
Figures 5, 6 and 7 illustrate the ascension of EBs in each
of these scenarios. The domain illustrated represents the
cervical epithelium, oriented with the vaginal boundary
at the base. The model is subject to periodic boundary
conditions on the lateral boundaries, to recover the 3D
geometry. Following [2], we impose C = 0 on the lower
boundary, since the lower genital tract is inhospitable to
chlamydial infection, and impose a zero-flux condition on
the top boundary to represent the effects of the cervical
mucus plug. In each simulation, a deposit of extracellu-
lar chlamydiae is initially randomly distributed in a stripe
close to the lower boundary.
a b c d e
f g h i j
Figure 5 Ascension of C. trachomatis in the cervix in the absence of vaccination. Results illustrated are the number of extracellular chlamydiae
at each spatial location at (a) 0 hours, (b) 24 hours, (c) 48 hours, (d) 72 hours, (e) 96 hours, (f) 120 hours, (g) 144 hours, (h) 372 hours, (i) 384 hours
and (j) 408 hours. The infection quickly spreads through the cervix and beyond, with reinfections occurring periodically in the lower cervix due to
lysis of infected epithelial cells.
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Figure 6 Progression of C. trachomatis infection through the cervix under a moderate vaccine-induced antibody level. Results illustrated
are the number of extracellular chlamydiae at each spatial location at (a) 0 hours, (b) 24 hours, (c) 48 hours, (d) 72 hours and (e) 144 hours. While
the majority of the extracellular chlamydiae are removed due to the antibody, some chlamydiae do ascend to above the cervix.
In the absence of the antibody (Figure 5), the infection
builds rapidly and ascends the cervix in a manner reminis-
cent of a travelling wave. The infection progresses to above
the cervix (not modelled here), with potentially serious
implications upon reproductive health. Infection in the
cervix itself is also maintained, with lysis of infected cells
generating recurring peaks in EB number (Figure 5(h)).
With a moderate antibody level (Figure 6), the short-term
behaviour is similar to that of Figure 5; however, after
72 hours the majority of the EBs have been successfully
removed as a result of the antibody stimulating the
immune response and hindering cell infection. While the
situation is somewhat improved by the presence of the
antibody, a small number of EBs do still ascend to the
upper cervical boundary (Figure 6(e)). For a high anti-
body level (Figure 7) the infectious extracellular chlamy-
diae are quickly removed by the immune response; the
infection is successfully prevented from ascending to the
upper reproductive tract. For the demonstrative param-
eters used here, the infection is cleared within 60 hours;
a timescale similar to those observed in related animal
inoculation experiments [19].
Discussion
The current release of STI-GMaS (version 1.2) incorpo-
rates three Chlamydia models: that of [9], a temporal
model operating on the tissue scale, the outputs of which
compare readily to the results of many animal experi-
ments; that of [2], which elucidates the spatial ascension
of an infection up the female genital tract; and a new
extension of the latter model (described above) to examine
the effectiveness of a hypothetical vaccine. This vaccine
model demonstrates how existing models can be read-
ily adapted and reused through STI-GMaS, and exhibits
much scope for coupling to laboratory experiments to
inform parameter values. With parameter values more
accurately determined to model specific vaccines, the
model will be in a position to address questions regarding
appropriate vaccine dosage and optimisation of immune
response times to remove infections efficiently.
While this article has focused upon the use of STI-
GMaS for in silico experimentation, there is also great
scope for its use as part of e.g. Approximate Bayesian
Computation (ABC) schemes for inferringmodel parame-
ters from data [20-22]. These schemes weight parameters
according to the closeness of a forward simulation of a
model (such as those produced by STI-GMaS) to true
data, allowing for good parameter estimation even in
the presence of extremely complicated disease dynamics.
Hence, STI-GMaS has the potential to facilitate model
simulation, parameterisation and inference within the
same software package.
The design of STI-GMaS has extensibility at its core:
further models will be added to the software in due
course, subject to strict standards of clear model annota-
tion and parameterisation being demonstrably met. The
framework for incorporating these models is now well-
defined, with templates in use for creation of codes for
a b c d
Figure 7 Evolution of C. trachomatis infection in the cervix under a high vaccine-induced antibody level. Results illustrated are the number
of extracellular chlamydiae at each spatial location at (a) 0 hours, (b) 20 hours, (c) 40 hours and (d) 60 hours. The infection is quickly removed by the
immune system, and does not ascend to above the cervix.
Nelson et al. BMC Systems Biology 2014, 8:66 Page 8 of 9
http://www.biomedcentral.com/1752-0509/8/66
CHASTE simulations and for the graphical user interface
itself. While we do not expect non-theoretical users to
add new models to the software themselves, these tem-
plates ease the developers’ task of introducing newmodels
as they arise, and the environment’s open source design
makes the corresponding codes accessible to researchers
of any background who do wish to become more familiar
with the computational principles.
The models discussed herein exhibit great scope for
future extension. Currently, a key limitation of spatial
models lies in their focus upon only cervical tissue. Expan-
sion of the modelled domain to include regions up to the
Fallopian tubes, would allow for investigations of scarring,
inflammation and PID. One direct target for such a model
is the “arrested immunity” hypothesis proposed by [23],
which suggests that although early antibiotic treatment
can cure the chlamydial infection, it can also interrupt
the development of immunity. Consequently, the preva-
lence of Chlamydia in the population does not decline
but actually increases. However, early treatment can pre-
vent the development of PID. The experimentalist may
therefore question whether there exists a time frame dur-
ing which antibiotic intervention can prevent PID but also
allow the host to develop immunity, potentially leading
to new antibiotic interventions. The mathematical model
presented here exhibits many of the requirements of such
a theoretical investigation, although it does not currently
represent adequate regions of the host anatomy.
We note that while work to date has focused upon
within-host models of Chlamydia, targets for future
development within the STI-GMaS environment are to
incorporate both population-scale models, and models of
other STIs. Many of the modelling techniques deployed
here transfer directly to within-host models of other infec-
tions: models of gonorrhoea show particular similarity to
those described above and, while having a different patho-
genesis to that of Chlamydia, syphilis and viral infections
such as Herpes simplex virus, Human papillomavirus and
viral hepatitis could be represented with models employ-
ing a highly similar process. Future work will examine the
above infections in isolation, as well as co-infections, and
will incoporate such models into the STI-GMaS software.
Conclusions
The STI-GMaS environment represents, to the authors’
knowledge, the first software designed explicitly for in sil-
ico simulation of STI models by non-theoreticians. Albeit
a growing field, mathematical modelling of STIs is in its
relative infancy, with little uptake of models in biological
domains. This software presents a novel route to bridging
the gap between computational and clinical/experimental
disciplines, and in doing so will stimulate dissemina-
tion and uptake of both existing and new theoretical
models.
As described above, the implementation of Chlamydia
models to date constitutes a template that can be easily
extended to other STIs. Such extensions will be included
in future releases. A key target for future development will
be to include within STI-GMaS a full geometric descip-
tion of the genital tract, which can be deployed readily
within new models, regardless of the infection under con-
sideration. In parallel, key parameters will be identified in
each of the key subtissues and made available across mod-
els. In doing so, STI-GMaS will improve upon the current
necessity for models to be heavily relient on phenomeno-
logical parameter values.
We remark that, while STI-GMaS has made head-
way in making computational models more accessible, a
true bridging of disciplines would benefit greatly from a
bidirectional exchange of information. The task of mak-
ing experimental data available through repositories with
robust annotation is considerable and unresolved, and has
been the focus of many other VPH-related initiatives; see
e.g. [24] for details. Such integration of experimental data
remains a long-term target for STI-GMaS.
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